Immunotherapy Following Chemotherapy May Benefit Metastatic Ovarian Cancer Patients

Immunotherapy Following Chemotherapy May Benefit Metastatic Ovarian Cancer Patients
Women with metastatic ovarian cancer treated with chemotherapy prior to surgery have higher levels of specific immune cells with the ability to attack tumor cells. These findings suggest that immunotherapy designed to remove the breaks of immune cells may be used in these patients to enhance anti-tumor responses and improve disease control. The study, titled "Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma", was published in Clinical Cancer Research, and developed by researchers at the Queen Mary University of London, in the U.K. “We are studying a type of ovarian cancer called high-grade serous ovarian cancer (HGSC), which is quite difficult to treat for two main reasons: first, it is often detected after it has spread quite extensively in the body; and second, although the disease can respond well to the first chemotherapy treatments, it often relapses and becomes more difficult to treat," Frances R. Balkwill, PhD, professor of cancer biology at Barts Cancer Institute in Queen Mary University of London, United Kingdom, said in a press release. Therefore we need to find other treatment options after the initial treatment is given.” Previous research has shown that chemotherapy can have a dual role in fighting some tumors, inducing both tumor cell death and stimulating the expansion and activation of anti-tumor immune cells. Now, the researchers wanted to address
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *